A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)

NCT04988087 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Sjogren Syndrome
Mixed Connective Tissue Disease

Interventions

DRUG: MHV370
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals